Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev 2015; 41:170-8; PMID:25498841; http://dx.doi.org/10.1016/j.ctrv.2014.11.003
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19:1423-37; PMID:24202395; http://dx.doi.org/10.1038/nm.3394
   PubMed Web of Science ®Google Scholar
• Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122:787-95; PMID:22378047; http://dx.doi.org/10.1172/JCI59643
   PubMed Web of Science ®Google Scholar
• De PM, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013; 23:277-86; PMID:23518347; http://dx.doi.org/10.1016/j.ccr.2013.02.013
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Markowitz J, Carson WE. Review of S100A9 biology and its role in cancer. Biochim Biophys Acta 2013; 1835:100-9; PMID:23123827; http://dx.doi.org/10.1016/j.bbcan.2012.10.003.
   PubMed Web of Science ®Google Scholar
• Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235-49; PMID:18809714; http://dx.doi.org/10.1084/jem.20080132
   PubMed Web of Science ®Google Scholar
• Becker A, Hokamp NG, Zenker S, Flores-Borja F, Barzcyk K, Varga G, Roth J, Geyer C, Heindel W, Bremer C et al. Optical in vivo imaging of the alarmin s100a9 in tumor lesions allows for estimation of the individual malignant potential by evaluation of tumor-host cell interaction. J Nucl Med 2015; 56:450-6; PMID:25678492; http://dx.doi.org/10.2967/jnumed.114.146688
   PubMed Web of Science ®Google Scholar
• Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348:74-80; PMID:25838376; http://dx.doi.org/10.1126/science.aaa6204
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol 2014; 193:3835-41; PMID:25281753; http://dx.doi.org/10.4049/jimmunol.1401572
   PubMed Web of Science ®Google Scholar
• Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol 2014; 25:2433-42; PMID:25223485; http://dx.doi.org/10.1093/annonc/mdu452
   PubMed Web of Science ®Google Scholar
• Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94:107-16; PMID:24217091; http://dx.doi.org/10.1038/labinvest.2013.130
   PubMed Web of Science ®Google Scholar
• Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007; 109:1499-505; PMID:17340590; http://dx.doi.org/10.1002/cncr.22588
   PubMed Web of Science ®Google Scholar
• Wang YU, Liu AN, Zhao SH. Association between B7-H1 expression and bladder cancer: a meta-analysis. Genet Mol Res 2015; 14:1277-86; PMID:25730066; http://dx.doi.org/10.4238/2015.February.13.6.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; http://dx.doi.org/10.1016/j.ccell.2015.03.001
   PubMed Web of Science ®Google Scholar
• Baksh K, Weber J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin Oncol 2015; 42:363-77; PMID:25965355; http://dx.doi.org/10.1053/j.seminoncol.2015.02.015
   PubMed Web of Science ®Google Scholar
• Källberg E, Vogl T, Liberg D, Olsson A, Björk P, Wikström P, Bergh A, Roth J, Ivars F, Leanderson T. S100A9 interaction with TLR4 promotes tumor growth. PLoS One 2012; 7:e34207; PMID:22470535; http://dx.doi.org/10.1371/journal.pone.0034207
   PubMed Web of Science ®Google Scholar
• Hibino T, Sakaguchi M, Miyamoto S, Yamamoto M, Motoyama A, Hosoi J, Shimokata T, Ito T, Tsuboi R, Huh NH. S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. Cancer Res 2013; 73:172-83; PMID:23135911; http://dx.doi.org/10.1158/0008-5472.CAN-11-3843
   PubMed Web of Science ®Google Scholar
• Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Björk A, Olsson A, Leanderson T. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006; 66:1768-78; PMID:16955399; http://dx.doi.org/10.1002/pros.20509
   PubMed Web of Science ®Google Scholar
• Gupta N, Al UO, Shen L, Pili R. Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. Onco Targets Ther 2014; 7:223-34; PMID:24600234; http://dx.doi.org/10.2147/OTT.S53524.
   PubMed Web of Science ®Google Scholar
• Leanderson T, Ivars F. S100A9 and tumor growth. Oncoimmunology 2012; 1:1404-5; PMID:23243608; http://dx.doi.org/10.4161/onci.21027
   PubMed Web of Science ®Google Scholar
• Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, Roth J, Ivars F, Leanderson T. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009; 7:e97; PMID:19402754; http://dx.doi.org/10.1371/journal.pbio.1000097.
   PubMed Web of Science ®Google Scholar
• Ramachandran IR, Lin C, hase T, Gabrilovich DI, Nefedova Y. A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma. Blood 2014; 124 (21); 5729-5729
   Web of Science ®Google Scholar
• Nacken W, Sopalla C, Propper C, Sorg C, Kerkhoff C. Biochemical characterization of the murine S100A9 (MRP14) protein suggests that it is functionally equivalent to its human counterpart despite its low degree of sequence homology. Eur J Biochem 2000; 267:560-5; PMID:10632726; http://dx.doi.org/10.1046/j.1432-1327.2000.01040.x
   PubMedGoogle Scholar
• Steding CE, Wu ST, Zhang Y, Jeng MH, Elzey BD, Kao C. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 2011; 133:221-38; PMID:21453419; http://dx.doi.org/10.1111/j.1365-2567.2011.03429.x
   PubMed Web of Science ®Google Scholar
• Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol 2013; 13:777-89; PMID:24113868; http://dx.doi.org/10.1038/nri3536
   PubMed Web of Science ®Google Scholar
• Croucher DR, Saunders DN, Lobov S, Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer 2008; 8:535-45; PMID:18548086; http://dx.doi.org/10.1038/nrc2400
   PubMed Web of Science ®Google Scholar
• Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19:1264-72; PMID:24056773; http://dx.doi.org/10.1038/nm.3337
   PubMed Web of Science ®Google Scholar
• Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev 2014; 25:377-90; PMID:25200249; http://dx.doi.org/10.1016/j.cytogfr.2014.07.018
   PubMed Web of Science ®Google Scholar
• Tidehag V, Hammarsten P, Egevad L, Granfors T, Stattin P, Leanderson T, Wikström P, Josefsson A, Hägglöf C, Bergh A. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome. Eur J Cancer 2014; 50:1829-35; PMID:24726733; http://dx.doi.org/10.1016/j.ejca.2014.03.278.
   PubMed Web of Science ®Google Scholar
• Fang WY, Chen YW, Hsiao JR, Liu CS, Kuo YZ, Wang YC, Chang KC, Tsai ST, Chang MZ, Lin SH et al. Elevated S100A9 expression in tumor stroma functions as an early recurrence marker for early-stage oral cancer patients through increased tumor cell invasion, angiogenesis, macrophage recruitment and interleukin-6 production. Oncotarget 2015; 6:28401-24; PMID:26315114; http://dx.doi.org/10.18632/oncotarget.4951
   PubMed Web of Science ®Google Scholar
• Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 2015; 3:136-48; PMID:25370534; http://dx.doi.org/10.1158/2326-6066.CIR-14-0036
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14:1014-22; PMID:24048123; http://dx.doi.org/10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology 2013; 2:e26536; PMID:24404424; http://dx.doi.org/10.4161/onci.26536
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014; 3:e27878; PMID:24800173; http://dx.doi.org/10.4161/onci.27878
   PubMed Web of Science ®Google Scholar
• Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 2014; 21:39-49; PMID:23832118; http://dx.doi.org/10.1038/cdd.2013.84
   PubMed Web of Science ®Google Scholar
• Ngiow SF, McArthur GA, Smyth MJ. Radiotherapy complements immune checkpoint blockade. Cancer Cell 2015; 27:437-8; PMID:25873170; http://dx.doi.org/10.1016/j.ccell.2015.03.015
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, Weicheslbaum RR, Fu YX. Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. Oncoimmunology 2014; 3:e28499; PMID:25050217; http://dx.doi.org/10.4161/onci.28499
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124:687-95; PMID:24382348; http://dx.doi.org/10.1172/JCI67313
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Maio M, Robert C. Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies. Semin Oncol 2015; 42:429-35; PMID:25965361; http://dx.doi.org/10.1053/j.seminoncol.2015.02.010
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558-62; PMID:25428503; http://dx.doi.org/10.1038/nature13904
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P et al. Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472-508; PMID:25537519; http://dx.doi.org/10.18632/oncotarget.2998
   PubMed Web of Science ®Google Scholar
• Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; 29:4022-8; PMID:21931019; http://dx.doi.org/10.1200/JCO.2011.35.6295
   PubMed Web of Science ®Google Scholar
• Carducci MA, Armstrong AJ, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang NJ et al. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod (TASQ) in Men with Metastatic Castrate Resistant Prostate Cancer (mCRPC). Abstract presented at the 18th ECCO - 40th ESMO European Cancer Congress, 25–29 September Vienna, Austria. 2015.
   Google Scholar
• Holzel M, Bovier A, Tuting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 2013; 13:365-76; PMID:23535846; http://dx.doi.org/10.1038/nrc3498
   PubMed Web of Science ®Google Scholar
• Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014; 74:5057-69; PMID:25082815; http://dx.doi.org/10.1158/0008-5472.CAN-13-3723
   PubMed Web of Science ®Google Scholar
• Kim HR, Hwang KA, Park SH, Kang I. IL-7 and IL-15: biology and roles in T-Cell immunity in health and disease. Crit Rev Immunol 2008; 28:325-39; PMID:19166383; http://dx.doi.org/10.1615/CritRevImmunol.v28.i4.40
   PubMed Web of Science ®Google Scholar
• Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel) 2011; 3:3856-93; PMID:24213115; http://dx.doi.org/10.3390/cancers3043856
   PubMedGoogle Scholar
• Xiao Y, Rabe C, Kowanetz M, Powles T, Vogelzang NJ, Petrylak DP, Loriot Y, Denker M, Nakamura R, Wu QJ et al. Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer. J ImmunoTher Cancer 2014; S3-131; http://dx.doi.org/10.1186/2051-1426-2-S3-P131
   Google Scholar
• Zhu Y, Hawkins WG, DeNardo DG. Regramming myeloid responses to improve cancer immunotherapy. Oncoimmunology 2015; 4:e974399; PMID:26155432; http://dx.doi.org/10.4161/2162402X.2014.974399
   PubMedGoogle Scholar
• Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res 2015; 75:2139-45; PMID:25977340; http://dx.doi.org/10.1158/0008-5472.CAN-15-0255
   PubMed Web of Science ®Google Scholar